{"transactions":[{"id":760407,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":43553,"kind":"organization","name":"GC Corp.","position":1,"cik":"0001931382","reported_name":"GC Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":43554,"kind":"organization","name":"GC Cell Corp","position":2,"cik":"0001931891","reported_name":"GC Cell Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-28T20:34:23.000Z","date":"2026-05-11","kind":"purchase","planned":false,"acquired":true,"shares":347222,"price":11.52,"value":3999997.44,"ownership":{"direct":false,"nature":"By GC Cell Corporation"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by GC Cell Corporation. GC Corp., a public Korean holdings company, is the parent company of GC Cell Corporation and is ultimately controlled by its board of directors. As of March 26, 2026, the board consists of: Mr. Yong-Jun Huh, Huh Il-Sup, Park Yong-Tae, Kang Joonho, and Lee Choonwoo. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and GC Cell Corporation and each disclaims beneficial ownership of all shares held by such entities, except to the extent of any pecuniary interest therein."}],"balance_after":1607734,"source":{"system":"sec-edgar","filing":"0001931382-26-000007","document":"form4-05282026_080518.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1931891/000193138226000007/form4-05282026_080518.xml","form_type":"4"}},{"id":760406,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":43553,"kind":"organization","name":"GC Corp.","position":1,"cik":"0001931382","reported_name":"GC Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":43554,"kind":"organization","name":"GC Cell Corp","position":2,"cik":"0001931891","reported_name":"GC Cell Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-28T20:34:23.000Z","date":"2026-05-11","kind":"purchase","planned":false,"acquired":true,"shares":1085069,"price":11.52,"value":12499994.88,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"GC Corp., a public Korean holdings company, is ultimately controlled by its board of directors. As of March 26, 2026, the board consists of: Mr. Yong-Jun Huh, Huh Il-Sup, Park Yong-Tae, Kang Joonho, and Lee Choonwoo. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and each disclaims beneficial ownership of all shares held by GC Corp., except to the extent of any pecuniary interest therein."}],"balance_after":4391969,"source":{"system":"sec-edgar","filing":"0001931382-26-000007","document":"form4-05282026_080518.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1931891/000193138226000007/form4-05282026_080518.xml","form_type":"4"}},{"id":1450584,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":43553,"kind":"organization","name":"GC Corp.","position":1,"cik":"0001931382","reported_name":"GC Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":43554,"kind":"organization","name":"GC Cell Corp","position":2,"cik":"0001931891","reported_name":"GC Cell Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-07-23T00:25:40.000Z","date":"2024-07-22","kind":"exercise","planned":false,"acquired":false,"shares":62181,"ownership":{"direct":false,"nature":"By GC Cell Corporation"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by GC Cell Corporation. GC Corp., a public Korean holdings company, is the parent company of GC Cell Corporation and is ultimately controlled by its board of directors, consisting of Mr. Yong-Jun Huh, Huh II-Sup, Park Yong-Tae and Kim Seok-Hwa.  Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and GC Cell Corporation and each disclaims beneficial ownership of all shares held by such entities, except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":62181},"source":{"system":"sec-edgar","filing":"0001415889-24-019907","document":"form4-07232024_120735.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1931891/000141588924019907/form4-07232024_120735.xml","form_type":"4"}},{"id":1450583,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":43553,"kind":"organization","name":"GC Corp.","position":1,"cik":"0001931382","reported_name":"GC Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":43554,"kind":"organization","name":"GC Cell Corp","position":2,"cik":"0001931891","reported_name":"GC Cell Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2024-07-23T00:25:40.000Z","date":"2024-07-22","kind":"exercise","planned":false,"acquired":false,"shares":292791,"ownership":{"direct":false,"nature":"By GC Cell Corporation"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by GC Cell Corporation. GC Corp., a public Korean holdings company, is the parent company of GC Cell Corporation and is ultimately controlled by its board of directors, consisting of Mr. Yong-Jun Huh, Huh II-Sup, Park Yong-Tae and Kim Seok-Hwa.  Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and GC Cell Corporation and each disclaims beneficial ownership of all shares held by such entities, except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":292791},"source":{"system":"sec-edgar","filing":"0001415889-24-019907","document":"form4-07232024_120735.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1931891/000141588924019907/form4-07232024_120735.xml","form_type":"4"}},{"id":1450582,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":43553,"kind":"organization","name":"GC Corp.","position":1,"cik":"0001931382","reported_name":"GC Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":43554,"kind":"organization","name":"GC Cell Corp","position":2,"cik":"0001931891","reported_name":"GC Cell Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-07-23T00:25:40.000Z","date":"2024-07-22","kind":"exercise","planned":false,"acquired":false,"shares":330095,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"GC Corp., a public Korean holdings company, is ultimately controlled by its board of directors, consisting of Mr. Yong-Jun Huh, Huh II-Sup, Park Yong-Tae and Kim Seok-Hwa. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and each disclaims beneficial ownership of all shares held by CG Corp., except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":330095},"source":{"system":"sec-edgar","filing":"0001415889-24-019907","document":"form4-07232024_120735.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1931891/000141588924019907/form4-07232024_120735.xml","form_type":"4"}},{"id":1450581,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":43553,"kind":"organization","name":"GC Corp.","position":1,"cik":"0001931382","reported_name":"GC Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":43554,"kind":"organization","name":"GC Cell Corp","position":2,"cik":"0001931891","reported_name":"GC Cell Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2024-07-23T00:25:40.000Z","date":"2024-07-22","kind":"exercise","planned":false,"acquired":false,"shares":667185,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"GC Corp., a public Korean holdings company, is ultimately controlled by its board of directors, consisting of Mr. Yong-Jun Huh, Huh II-Sup, Park Yong-Tae and Kim Seok-Hwa. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and each disclaims beneficial ownership of all shares held by CG Corp., except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":667185},"source":{"system":"sec-edgar","filing":"0001415889-24-019907","document":"form4-07232024_120735.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1931891/000141588924019907/form4-07232024_120735.xml","form_type":"4"}},{"id":1450580,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":43553,"kind":"organization","name":"GC Corp.","position":1,"cik":"0001931382","reported_name":"GC Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":43554,"kind":"organization","name":"GC Cell Corp","position":2,"cik":"0001931891","reported_name":"GC Cell Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-07-23T00:25:40.000Z","date":"2024-07-22","kind":"purchase","planned":false,"acquired":true,"shares":416666,"price":12,"value":4999992.0,"ownership":{"direct":false,"nature":"By GC Cell Corporation"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The shares were purchased in the Issuer's initial public offering."}],"balance_after":1260512,"source":{"system":"sec-edgar","filing":"0001415889-24-019907","document":"form4-07232024_120735.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1931891/000141588924019907/form4-07232024_120735.xml","form_type":"4"}},{"id":1450579,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":43553,"kind":"organization","name":"GC Corp.","position":1,"cik":"0001931382","reported_name":"GC Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":43554,"kind":"organization","name":"GC Cell Corp","position":2,"cik":"0001931891","reported_name":"GC Cell Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-07-23T00:25:40.000Z","date":"2024-07-22","kind":"other","planned":false,"acquired":true,"shares":256316,"price":10.2,"value":2614423.2,"ownership":{"direct":false,"nature":"By GC Cell Corporation"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Represents the conversion of outstanding simple agreement for future equity in the amount of $2,614,424.28 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by GC Cell Corporation. GC Corp., a public Korean holdings company, is the parent company of GC Cell Corporation and is ultimately controlled by its board of directors, consisting of Mr. Yong-Jun Huh, Huh II-Sup, Park Yong-Tae and Kim Seok-Hwa.  Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and GC Cell Corporation and each disclaims beneficial ownership of all shares held by such entities, except to the extent of any pecuniary interest therein."}],"balance_after":843846,"source":{"system":"sec-edgar","filing":"0001415889-24-019907","document":"form4-07232024_120735.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1931891/000141588924019907/form4-07232024_120735.xml","form_type":"4"}},{"id":1450578,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":43553,"kind":"organization","name":"GC Corp.","position":1,"cik":"0001931382","reported_name":"GC Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":43554,"kind":"organization","name":"GC Cell Corp","position":2,"cik":"0001931891","reported_name":"GC Cell Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-07-23T00:25:40.000Z","date":"2024-07-22","kind":"exercise","planned":false,"acquired":true,"shares":62181,"ownership":{"direct":false,"nature":"By GC Cell Corporation"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by GC Cell Corporation. GC Corp., a public Korean holdings company, is the parent company of GC Cell Corporation and is ultimately controlled by its board of directors, consisting of Mr. Yong-Jun Huh, Huh II-Sup, Park Yong-Tae and Kim Seok-Hwa.  Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and GC Cell Corporation and each disclaims beneficial ownership of all shares held by such entities, except to the extent of any pecuniary interest therein."}],"balance_after":587530,"source":{"system":"sec-edgar","filing":"0001415889-24-019907","document":"form4-07232024_120735.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1931891/000141588924019907/form4-07232024_120735.xml","form_type":"4"}},{"id":1450577,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":43553,"kind":"organization","name":"GC Corp.","position":1,"cik":"0001931382","reported_name":"GC Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":43554,"kind":"organization","name":"GC Cell Corp","position":2,"cik":"0001931891","reported_name":"GC Cell Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-07-23T00:25:40.000Z","date":"2024-07-22","kind":"exercise","planned":false,"acquired":true,"shares":292791,"ownership":{"direct":false,"nature":"By GC Cell Corporation"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by GC Cell Corporation. GC Corp., a public Korean holdings company, is the parent company of GC Cell Corporation and is ultimately controlled by its board of directors, consisting of Mr. Yong-Jun Huh, Huh II-Sup, Park Yong-Tae and Kim Seok-Hwa.  Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and GC Cell Corporation and each disclaims beneficial ownership of all shares held by such entities, except to the extent of any pecuniary interest therein."}],"balance_after":525349,"source":{"system":"sec-edgar","filing":"0001415889-24-019907","document":"form4-07232024_120735.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1931891/000141588924019907/form4-07232024_120735.xml","form_type":"4"}},{"id":1450576,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":43553,"kind":"organization","name":"GC Corp.","position":1,"cik":"0001931382","reported_name":"GC Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":43554,"kind":"organization","name":"GC Cell Corp","position":2,"cik":"0001931891","reported_name":"GC Cell Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-07-23T00:25:40.000Z","date":"2024-07-22","kind":"purchase","planned":false,"acquired":true,"shares":1666666,"price":12,"value":19999992.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The shares were purchased in the Issuer's initial public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"GC Corp., a public Korean holdings company, is ultimately controlled by its board of directors, consisting of Mr. Yong-Jun Huh, Huh II-Sup, Park Yong-Tae and Kim Seok-Hwa. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and each disclaims beneficial ownership of all shares held by CG Corp., except to the extent of any pecuniary interest therein."}],"balance_after":3306900,"source":{"system":"sec-edgar","filing":"0001415889-24-019907","document":"form4-07232024_120735.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1931891/000141588924019907/form4-07232024_120735.xml","form_type":"4"}},{"id":1450575,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":43553,"kind":"organization","name":"GC Corp.","position":1,"cik":"0001931382","reported_name":"GC Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":43554,"kind":"organization","name":"GC Cell Corp","position":2,"cik":"0001931891","reported_name":"GC Cell Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-07-23T00:25:40.000Z","date":"2024-07-22","kind":"other","planned":false,"acquired":true,"shares":294117,"price":10.2,"value":2999993.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the conversion of outstanding simple agreement for future equity in the amount of $3,000,000.00 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"GC Corp., a public Korean holdings company, is ultimately controlled by its board of directors, consisting of Mr. Yong-Jun Huh, Huh II-Sup, Park Yong-Tae and Kim Seok-Hwa. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and each disclaims beneficial ownership of all shares held by CG Corp., except to the extent of any pecuniary interest therein."}],"balance_after":1640234,"source":{"system":"sec-edgar","filing":"0001415889-24-019907","document":"form4-07232024_120735.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1931891/000141588924019907/form4-07232024_120735.xml","form_type":"4"}},{"id":1450574,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":43553,"kind":"organization","name":"GC Corp.","position":1,"cik":"0001931382","reported_name":"GC Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":43554,"kind":"organization","name":"GC Cell Corp","position":2,"cik":"0001931891","reported_name":"GC Cell Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-07-23T00:25:40.000Z","date":"2024-07-22","kind":"exercise","planned":false,"acquired":true,"shares":330095,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"GC Corp., a public Korean holdings company, is ultimately controlled by its board of directors, consisting of Mr. Yong-Jun Huh, Huh II-Sup, Park Yong-Tae and Kim Seok-Hwa. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and each disclaims beneficial ownership of all shares held by CG Corp., except to the extent of any pecuniary interest therein."}],"balance_after":1346117,"source":{"system":"sec-edgar","filing":"0001415889-24-019907","document":"form4-07232024_120735.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1931891/000141588924019907/form4-07232024_120735.xml","form_type":"4"}},{"id":1450573,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":43553,"kind":"organization","name":"GC Corp.","position":1,"cik":"0001931382","reported_name":"GC Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":43554,"kind":"organization","name":"GC Cell Corp","position":2,"cik":"0001931891","reported_name":"GC Cell Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-07-23T00:25:40.000Z","date":"2024-07-22","kind":"exercise","planned":false,"acquired":true,"shares":667185,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"GC Corp., a public Korean holdings company, is ultimately controlled by its board of directors, consisting of Mr. Yong-Jun Huh, Huh II-Sup, Park Yong-Tae and Kim Seok-Hwa. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and each disclaims beneficial ownership of all shares held by CG Corp., except to the extent of any pecuniary interest therein."}],"balance_after":1016022,"source":{"system":"sec-edgar","filing":"0001415889-24-019907","document":"form4-07232024_120735.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1931891/000141588924019907/form4-07232024_120735.xml","form_type":"4"}}]}